Prevalence and carrier frequency of Canavan disease in a South Indian community with implications for research and public health Authors: Rekha Aaron, Aaron Chapla, M Jayaprabha, Janane Elangovan, Roopa Kunthavai Chellappa, Asha Krishnamurthy, Ramya Raghavan, Mrinalini Peters, Maya Thomas, Sumita Danda Published: 2026 ABSTRACT AbstractCanavan disease (CD) is a progressive leukodystrophy characterized by the spongy degeneration of white matter in the brain. Only three reports from India have been elucidated the ASPA gene mutation in patients diagnosed with CD. At our center, two genetically confirmed cases of juvenile Canavan disease have been identified. Both patients possess a novel genetic variant in the ASPA gene, c.526G > A (p. Gly176Ser), which has been classified as pathogenic. A preliminary study conducted at our centre suggested the presence of a founder effect within this population. Hence, the current study aimed to analyse the cross-sectional prevalence and carrier frequency of the disease and confirm the founder effect. Five hundred seventy-five blood samples were collected from individuals in this community after obtaining informed, written consent. The ASPA gene, specifically exon 3, was analysed utilizing an in-house developed, cost-effective allele-specific PCR approach in all samples. Three short tandem repeat (STR) markers—D17S1828, D17S919, and D17S1298—were employed to examine the founder effect of the mutation by fragment analysis. The carrier frequency in our study population was found to be 1 in 23, higher than that reported in the Jewish population. The allele-specific PCR technique proved to be sensitive and cost-effective for mass screening. All identified carriers displayed specific variations in the 23 heterozygous allelic repeats. At the same time, the affected individuals manifested homozygous alleles for the D17S1828 marker, confirming that this variant is indigenous to the population under study. The D17S919 marker (18/19 repeats) was absent in the control cohort but present in the community under investigation, further substantiating the founder effect. Furthermore, the study identified other potential genetic disorders in this community that warrant further investigation. This study underscores the critical importance of carrier screening in communities characterized by high consanguinity to mitigate the prevalence of recessive disorders in future generations. The elevated carrier frequency observed in this community relative to that in Ashkenazi Jews points to a potential underestimation of prevalence, this might be due to the limited number of community-based studies conducted on rare diseases.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-52947-0.Keywords: Canavan disease, Population, Carrier, Prevalence, Haplotype, Founder effectSubject terms: Genetics, Neuroscience Introduction Canavan disease [CD] or Aspartoacylase deficiency is a progressive neurodegenerative disorder, inherited as an autosomal recessive disorder linked with a gene locus ASPA on chromosome 17, which encodes the aspartoacylase enzyme. This zinc carboxypeptidase converts N-acetyl-L-aspartic acid [NAA] to aspartate and acetate. The absence of this enzyme results in the accumulation of NAA in the brain. ASPA is primarily found in oligodendrocyte progenitor cells and oligodendrocytes in the brain, with smaller amounts also detected in microglia and the brainstem. A recent study by Wei et al., has shown that the pathogenesis of CD is not solely because of NAA accumulation but also through other NAA-associated signaling mechanisms1. The severity of clinical presentation depends on the degree of ASPA residual activity. Genetic testing for pathogenic variants in the ASPA gene is crucial for a definitive diagnosis of Canavan disease (CD). Over 50 mutations have been discovered in the human ASPA gene, mostly involving missense variants in the coding region. These mutations typically lead to the loss of ASPA enzymatic activity. The onset and severity of CD depend on the specific mutation present. A clear genotype-phenotype correlation is now possible in the mildest cases with the highest residual activity of the enzyme2. NAA serves as a molecular marker and plays a vital role in maintaining the metabolic integrity of oligodendrocytes. Infantile ASPA deficiency is prevalent in Ashkenazi Jews and less common in the non-Jewish population. The overall prevalence of CD is 1 in 200,000 to 400,000 (Mendes et al. 2017), whereas the prevalence in the Ashkenazi population is around 1 in 500 to 1 in 6700. In Jewish patients with CD, two primary mutations, c.854 A > C (p.Glu285Ala) and c.693 C > A (p.Y231X), have been identified in 98% of cases3. Conversely, the most common mutation in non-Jewish patients is c.914 C > A (p.Ala305Glu) (40%–48% of CD alleles). This mutation has been associated with severe and mild Canavan disease phenotypes. There are three clinically distinct phenotypes of CD, congenital form with severe symptoms in the first few weeks of life; the infantile/neonatal form, the most common form in which the disease is apparent by 6 months of age; and the juvenile form/mild form, in which the disease is evident by the age of 4 or 5 years. Early signs of the disease include irritability and hypotonia with poor head control. From 3 to 6 months, macrocephaly is evident with delayed head control, followed by progressive delay in achieving age-appropriate milestones. As the disease progresses, optic atrophy develops, leading to increased irritability, sleep disturbances, feeding difficulties, and seizures in affected children. The prognosis remains poor, with a high rate of mortality reported in early childhood4. However, individuals with milder forms of the disease can survive into their second decade of life and beyond. In contrast to the infantile CD, the juvenile variant is less common and presents with a normal period in infancy or only mild delay in motor milestones. Most children with mild disease are normocephalic. They present with variable symptoms, including progressive ataxia, nystagmus, visual difficulties, and other neurological manifestations. Failing to perform an MRI of the brain with MRS or check urine NAA levels significantly increases the risk of missing a CD diagnosis in mild cases. Only three reports from India have characterized the ASPA mutation in patients with CD5,6. Mild/Juvenile CD is less common than severe CD (Clayton et al. 2020). Previously identified two cases of Juvenile Canavan disease in the Devanga Chettiyar community near Thiruvanamalai district, Tamil Nadu have been confirmed with the presence of a novel homozygous missense variant c.526G > A (p.Gly176Ser) proximal to the donor splice site. This pathogenic variant was found to be segregating with the disease in the same community. Hence, we have aimed to study the prevalence of CD and carrier status in this closely knitted community. The community is spread across three neighboring villages. Due to inbreeding, there is a suspected higher incidence of CD in this region, with at least 22 to 24 cases exhibiting a similar phenotype over the last 15 to 20 years. However, there is no information available to definitively confirm these cases as CD. The earlier study suggested a possible high prevalence of mild or juvenile CD in this community. They identified that the founder effect for this variant may have originated from a common ancestor7. Therefore, we aimed to study the cross-sectional prevalence and carrier frequency of CD and to confirm the founder effect by screening a group of controls & cases from the same community by microsatellite analysis. Patients & methods This study was approved by the Institutional Review Board (IRB MIN NO:12018 dated 24.04.2019) and initiated after receiving approval from the DPHPM (Director of Public Health & Preventive Medicine) and the primary health center. All experiments were performed in accordance with relevant guidelines and regulations. To screen for the specific disease-causing variant in the ASPA, we developed a cost-effective method using Allele-specific PCR. All samples underwent DNA extraction followed by variant screening using Allele-specific PCR.Genomic DNA was extracted from peripheral blood using the standard Qiagen kit method. We designed primers for the ASPA gene exon 3 (ENST00000263080.3) and also primers specific for the variant. In addition to that, we designed Allele-specific PCR (AS-PCR) primers for the ASPA novel variant c.526G > A (p.Gly176Ser) using Primer3 software. AS-PCR was first standardized in patient and healthy samples using EmeraldAmp® GT PCR Master Mix (cat no.RR310A, Takara Bio Inc, Japan), validated by Sanger sequencing following the standard protocol and the PCR products were analysed on 2% agarose gel. The primer details are provided in the Table 1. Table 1The primer details used for AS-PCR (wildtype/mutant/common reverse) and Sanger sequencing (ASPA ex3 forward and reverse).Primer nameSequencesASPA 526G(wild type) forwardCATAGCCAAGTATCCTGTTGASPA 526 A(mutant)forwardCATAGCCAAGTATCCTGTTAASPA 526(common)reverseGGTTGGTCTCTGGTAGGCACAASPA EX3forwardATCTGTAGAGAGCTGGACCACAASPA EX3reverseTGAGCTGAGATCACACCATCGG The primer details used for AS-PCR (wildtype/mutant/common reverse) and Sanger sequencing (ASPA ex3 forward and reverse). Further, PCR was performed in all patients, family members, and samples from the same community to confirm the zygosity of the variant. All samples were sequenced by amplifying exon 3 with a specific set of primers. Linkage analysis is typically conducted by typing short tandem repeat markers to identify the gene locus and the haplotype associated with a pathogenic variant. We used three STR markers D17S1828, D17S919 & D17S1298, which are located around 10.2 cM-14.69 cM near the ASPA gene locus, to identify the haplotype pattern to elucidate the founder effect of the mutation. PCR was standardized using fluorescent-labeled primers, followed by fragment analysis with LIZ-600 as the size standard. The repeats were calculated manually based on the peak size. We included 20 carriers,30 non carriers and 20 samples from Vellore Tamilnadu region(a total of 70 samples) for STR analysis. The sample size was calculated, assuming a proportion p=0.5 using a confidence level of 95% (corresponding to a Z-score of 1.96) and a desired precision (margin of error) of ± 5%. Therefore, a minimum of 385 participants were required to achieve the desired precision and confidence level. Prevalence rates were calculated as the proportion of cases from total sample size. For allele frequency difference per STR locus was calculated using Chi-square test. Results Following multiple outreach camps and community education initiatives, a total of 575 blood samples were collected from three villages. Participation was voluntary and based on informed consent. In our study, we were unable to determine the prevalence of the disease since we did not identify any new cases. However, we found that the carrier frequency in our study population (25/575) was higher than that reported in the Jewish population (1 in 23, compared to 1 in 40 of the Jewish community). Allele-specific PCR (Fig. 1) was standardized and concordant with Sanger sequencing findings (Fig. 2), proving it to be a sensitive and cost-effective method for mass screening. The output of AS-PCR for the two affected cases and their family members is tabulated in Table 2. The output of the PCR is interpreted based on the presence of a band in wildtype/mutant PCR, confirming the corresponding allele. The internal control CFTR gene amplicon (400 bp) was amplified in every sample, ruling out other factors that can impede the amplification, such as the quality of DNA or mastermix contamination. The agarose gel (cropped image) showing typical banding pattern for homozygous, heterozygous wild type allele for the ASPA gene variant c.526G > A(p.Gly176Ser). For each sample two reactions has been performed one with a forward primer (wild type-WT) and a common reverse primer, the other with a mutant primer (MT) and a common reverse primer. Electropherogram confirming ASPA variant c.526G > A(p.Gly176Ser) in healthy control (wildtype), carrier (heterozygous) patient (homozygous) which is concordant with AS-PCR result (Sequencing shown is reverse strand C > T indicated by arrow mark). Samples 1,2,4,6,9,10 (lanes 1WT,1MT,2WT, 2MT,4WT,4MT,6WT,6MT 9WT,9MT,10WT&10MT) – heterozygous for the variant where the amplification is present in both WT & MT lane suggesting one allele is wild type and other allele is mutant. Sample 8(lane 8WT &8MT)-homozygous for the variant where the mutant allele alone is amplified results in 710 bp band. Samples 3,5,7 & 11 (lanes 3WT,3MT,5WT,5MT,7WT,7MT,11WT & 11MT)- wild type for the variant where the amplification is observed in WT-PCR and not in MT-PCR, where only internal control is amplified. The lane after 11MT & 7MT is 100 bp molecular size ladder for comparison of fragment size. The orignal gel picture is presented in supplemetary Fig. 1. Table 2The Allele specific PCR amplification results in two affected families; where 9 were heterozygous carriers. Amplification was be present in wildtype and mutant PCR reaction for the heterozygous carrier, whereas wildtype band was absent in homozygous sample and only wildtype band was be present in normal controls.Sample ID Wild type (normal) allele amplificationMutant (variant) Allele amplificationZygosity1CD1(patient 1)NoYesHomozygous2CD1 -motherYesYesHeterozygous3CD1 -fatherYesYesHeterozygous4CD1 -brotherYesYesHeterozygous5CD1- maternal grandmotherYesYesHeterozygous6CD1 -paternal grandmotherYesNoNormal/wildtype7CD1 -uncle 1(maternal)YesYesHeterozygous8CD1- aunty 1YesNoNormal/wildtype9CD1-aunty 2(maternal)YesNoNormal/wildtype10CD1- uncle 2YesNoNormal/wildtype11CD2 (patient 2)noYesHomozygous12CD2 -motherYesYesHeterozygous13CD2 -fatherYesYesHeterozygous14CD2 -paternal grandfatherYesNoNormal/wildtype15CD2- paternal grandmotherYesYesHeterozygous16CD2-- maternal grand motherYesNoNormal/wildtype17CD2 maternal grand fatherYesYesHeterozygous The Allele specific PCR amplification results in two affected families; where 9 were heterozygous carriers. Amplification was be present in wildtype and mutant PCR reaction for the heterozygous carrier, whereas wildtype band was absent in homozygous sample and only wildtype band was be present in normal controls. An intriguing finding was that two affected cases were related five generations back, and none of their other family members had the disease where the inbreeding is common (Fig. 3). This highlights the likelihood of disease occurrence in a close community is rare even though the carrier frequency is high. We hypothesize that the lower prevalence of the disease may be attributed to either our inability to confirm previous cases (estimated to be 15–20 cases) or to the presence of similar phenotypes that resulted in fatalities during the second or third decades of life, with only a subpopulation being screened. Therefore, genetic screening is crucial in such indigenous communities where multiple genetic disorders exist. The Family pedigree of the two cases related five generations back from the same community affected by Canavan disease (family CD1 & CD2) .The affected cases are indicated by arrow and carriers are indicated with a dot inside the symbol. The slash line indicates the deceased individual. For microsatellite analysis, the PCRs using fluorescently labelled primers were standardized in healthy samples and fragment analysis was done as per standard protocol. We analysed 20 heterozygous carriers, 30 non-carriers & 2 homozygous cases from the same community for three STR markers and compared the data with 20 non-carriers from another part of Tamilnadu (Vellore). The peak size is confirmed for each specific marker. The marker D17S1828 showed similar pattern in both the affected cases with 23/23 repeats that is inherited from the parents (Table 3; Fig. 4). All the carriers had heterozygous 23 allelic repeat compared to other population. None of the other group samples had the same STR repeats confirming that the variant is indigenous to this population due to founder effect (Table 4). The D17S919 marker 18/19 repeats were found to be absent in the Vellore cohort confirming the founder effect. The distribution and occurrence of STRs were found to be unique to this community, and it was statistically significant (D17S1298;p = 0.0013). The findings are summarized in Table 5. Table 3The STR markers repeats by fragment analysis in two Canavan cases displaying a similar pattern for marker D17S1828 in both the affected cases (23/23 repeats) inherited from the parents (carriers).Sample IDD17S1828D17S919D17S1298CD123/2318/197/9CD1.122/2318/208/9CD1.222/2319/207/8CD223/2318/189/9CD2.116/2318/197/9CD2.223/2318/197/9 The STR markers repeats by fragment analysis in two Canavan cases displaying a similar pattern for marker D17S1828 in both the affected cases (23/23 repeats) inherited from the parents (carriers). Representative chromatogram showing STR marker D17S1828 in a patient, carrier & control sample respectively (23/23repeats in patient,18/23 in carrier & 17/18 in control). The primers are HEX labelled. Table 4The STR repeats were identified in carriers (n = 16) from the same community and controls (n = 20) individuals from another district in Tamilnadu. The D17S1828 (23 allele) repeat is unique to this community, as it segregates with the pathogenic ASPA variant. For D17S919 marker (18) repeats and for D17S1298 (9) repeats are specific to the indigenous community and significantly different.Carriers (heterozygous)D17S1828D17S919D17S1298Controls (Vellore)D17S1828D17S919D17S1298C118/2312/187/9V117/1715/177/7C217/2318/199/9V221/2117/207/8C317/2318/209/9V317/1919/207/7C418/2318/197/9V419/2417/207/7C518/2318/197/9V519/2416/177/9C617/2318/199/9V617/1817/197/7C720/2318/199/9V716/1915/197/7C817/2318/199/9V817/1817/197/7C920/2318/196/9V917/2419/207/9C1022/2318/197/9V1017/1915/167/9C1117/2318/199/9V1118/1917/199/9C1220/2318/196/9V1219/1715/197/7C1320/2318/197/9V1319/1715/177/7C1417/2318/199/9V1419/1916/197/9C1518/2312/187/9V1516/1716/177/7C1618/2318/188/9V1617/1816/177/7V1716/1716/179/9V1817/2516/169/9V1916/2217/177/9V2017/1916/207/7 The STR repeats were identified in carriers (n = 16) from the same community and controls (n = 20) individuals from another district in Tamilnadu. The D17S1828 (23 allele) repeat is unique to this community, as it segregates with the pathogenic ASPA variant. For D17S919 marker (18) repeats and for D17S1298 (9) repeats are specific to the indigenous community and significantly different. Table 5Summary of the findings in this study including mutation, carrier frequency, STR markers in comparison with other studies or population.ParameterStudied communityJewish population or other studiesOther samples from TamilnaduCommentMutationc.526G > A(p.Gly176Ser)--Novel pathogenic variantCarrier frequency25/575 (1 in 23) for p.Gly176Ser1 in 40 forp.Glu285Ala & p.Tyr231Ter-Higher in studied populationSTR Marker: D17S182823 repeat allele in cases and carriers-23 repeats allele absent23 repeat allele specific to studied community (founder effect)STR Marker: D17S91918/19 genotype present in majority-None of them had 18/19 genotypeMarker present only in studied community; indicating founder effect.STR Marker: D17S1298Unique distribution of alleles, where 9 repeats is the major allele-Different pattern where 7 repeats is the major alleleStatistically significant (p = 0.0013) Summary of the findings in this study including mutation, carrier frequency, STR markers in comparison with other studies or population. 1 in 40 for p.Glu285Ala & p.Tyr231Ter While we did not identify any new cases of CD, we were able to trace other probable genetic diseases in this community, for which the genetic causes are currently unknown and have not been evaluated at our hospital before. Targeted genetic testing confirmed that these cases were negative for the ASPA variant. In two instances, exome sequencing revealed the genetic causes of early infantile epileptic encephalopathy due to an SCN8A gene variant in one case, and primary microcephaly related to an ASPM gene variant in another patient. This highlights the need for exome sequencing in the remaining cases to identify the possible causes of other genetic disorders which might be unique to the community. Discussion This is the first kind of study from India elucidating the prevalence of CD in an indigenous community. The incidence of CD is higher among the Ashkenazi Jewish population, although it has been reported in other ethnic groups with significantly lower frequencies. The definite prevalence of CD and clinical presentation in India are poorly determined. Gowda et al. reported retrospective data of 12 CD cases where six cases had mutations in the ASPA gene, the most extensive case series from India to date6. A Pilot study from India on NGS-based carrier screening for 88 diseases in 200 samples showed 0.5% Canavan disease carrier8. While international studies offer valuable epidemiological data and evidence-based screening methods, research in India is still limited, revealing significant gaps in diagnosis and public health responses. A recent study has reported variability among individuals with the same pathogenic p.G274R variant. This variability ranges from severe phenotypes, including axial hypotonia starting at three months of age, to a case of an 11-year-old with atypical mild symptoms.Another report describing three affected children from two Greek families with an unusually mild course of Canavan disease, with a compound heterozygous mutation in two individuals (Y288C; F295S) and a homozygous p.G274R variant. The above studies indicate that the p.G274R mutation might be a hot spot variant in other populations9–12. An earlier study from our center identified two cases with the same mutation in exon 3 of the ASPA gene, and later recognized that they both belonged to the same community. To our surprise, we recently found another patient at our clinic with the same mutation from a different region of Tamilnadu. We later confirmed that this family also belongs to the same community.This suggests that this mutation may be more common than previously recognized, possibly due to families relocating to various areas, leading to an underestimation of the underestimation of true incidence. In response to our camps and counseling, the community is currently much aware of genetic diseases and the higher probability of having affected generations if they marry within the community, hence the need for genetic screening is imperative in such an indigenous population. Through this study, we could determine the carriers and counsel them to prevent future generations from being affected by the disease. The outcomes of this work have the potential to significantly enhance global health and well-being by addressing critical gaps in rare disease detection and care. Currently, the lack of comprehensive epidemiological data impedes effective public health planning, optimal resource allocation, and the development of targeted therapies for rare genetic disorders. This is particularly evident in low- and middle-income countries like India, where community-based studies and screening programs for rare diseases such as Canavan disease and other leukodystrophies are virtually nonexistent. By conducting community-based genetic studies, researchers can identify population-specific variants and disease patterns, enabling the development of tailored newborn screening protocols. Early diagnosis through such programs can open pathways to timely interventions, including prenatal diagnosis, preimplantation genetic diagnosis (PGD), newborn screening, and emerging therapeutic options such as gene therapy or enzyme replacement. This proactive approach can drastically reduce the burden of disease, improve long-term outcomes, and enhance the quality of life for affected individuals and their families. Moreover, this research fosters awareness and builds genetic literacy within communities, promoting informed reproductive choices and reducing stigmatization of rare disorders. Conclusion This study underscores the critical role of carrier screening in communities with high consanguinity to educate future generations about autosomal recessive disorders which can impact the health and economy of a society. Although the project commenced with a focus on Canavan disease, it uncovered indications of additional genetic disorders within the community, signaling a promising avenue for further research. Notably, the carrier frequency observed was higher than that found among Ashkenazi Jews, which suggests a potential under representation of prevalence due to the scarcity of community-based studies on rare diseases like Canavan. Study highlights an exciting opportunity for enhanced community awareness and preventative measures in genetic health. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We gratefully acknowledge the Council of Scientific & Industrial Research (CSIR-HRDG Sanction No: 27 (0365)/20/EMRII) for funding this study under the extramural research scheme. We extend our sincere thanks to the Primary Health Centre, the Director of Public Health and Preventive Medicine (DPHPM), and the patients and their families for their invaluable support. We also appreciate the contributions of the laboratory staff, including Ms. Jency, Mr. Paramasivam as well as the Clinical Genetics and Molecular Endocrinology team at CMC, Vellore, who were involved in various aspects of this study. Author contributions Dr. Rekha A, Dr. Sumita Danda, Dr. Aaron C, Dr. Maya Thomas all are contributed to the study conception and design. Material preparation, data collection and analysis were performed by Dr. Rekha A Dr. Janane Elangovan, Dr. Roopa Kunthavai Chellappa, Dr. Asha Krishnamurthy, Ms. Jayaprabha M, Dr. Ramya R & Dr. Mrinalini P. The first draft of the manuscript was written by Dr. Rekha A and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Funding This study is funded by CSIR-HRDG [Sanction no:27(0365)/20/EMRII] under extramural research scheme. We also acknowledge institutional fluid research support for APC. Data availability The variant data that support this study has been deposited in Clinvar submission system with the accession code RCV002274814 (https://www.ncbi.nlm.nih.gov/clinvar/RCV002274814/). For any additional data requests, please contact the corresponding author. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The variant data that support this study has been deposited in Clinvar submission system with the accession code RCV002274814 (https://www.ncbi.nlm.nih.gov/clinvar/RCV002274814/). For any additional data requests, please contact the corresponding author.